Cytoplasmic expression of the ELAV-like protein HuR as a potential prognostic marker in esophageal squamous cell carcinoma
- PMID: 23873103
- DOI: 10.1007/s13277-013-1008-4
Cytoplasmic expression of the ELAV-like protein HuR as a potential prognostic marker in esophageal squamous cell carcinoma
Abstract
Esophageal squamous cell carcinoma (ESCC) is one of the most frequent cancers and a leading cause of death from cancer in China. The human ELAV-like protein HuR has been found to contribute to cancer development and progression through stabilizing a group of cellular mRNAs of cancer-related genes. In this study, we investigated the expression of HuR in a cohort of ESCC patients using immunohistochemical staining. HuR detected in the cytoplasm of cancer cells was positive in 46.6% of 58 ESCC specimens; 75.9% of these specimens had nuclear immunoreactivity for HuR. Cytoplasmic HuR expression was higher in cancer tissues compared to 20 matched adjacent noncancerous tissues. A clinicopathological study showed that cytoplasmic HuR expression was positively associated with lymph node metastasis, depth of tumor invasion, and advanced stage, whereas nuclear HuR expression was not correlated with any clinicopathological factors. Patients positive for cytoplasmic HuR expression had a cumulative 5-year survival rate of 25.3%, whereas it was 43.8% for patients negative for cytoplasmic HuR expression. In a multivariate analysis, cytoplasmic HuR expression was an independent prognostic factor, whereas nuclear positivity for HuR was not. Our results indicate that high cytoplasmic HuR expression is associated with positive lymph node metastasis, deep tumor invasion, high stage, and poor survival in ESCC. Thus, HuR is the first mRNA stability protein whose expression is associated with poor survival in esophageal cancer.
Similar articles
-
Increased expression of high-mobility group A2: A novel independent indicator of poor prognosis in patients with esophageal squamous cell carcinoma.J Cancer Res Ther. 2016 Oct-Dec;12(4):1291-1297. doi: 10.4103/0973-1482.180616. J Cancer Res Ther. 2016. PMID: 28169242
-
High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation.J Exp Clin Cancer Res. 2017 Jun 23;36(1):84. doi: 10.1186/s13046-017-0555-8. J Exp Clin Cancer Res. 2017. PMID: 28645305 Free PMC article.
-
Reduced nuclear and ectopic cytoplasmic expression of lysyl oxidase-like 2 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma.Hum Pathol. 2012 Jul;43(7):1068-76. doi: 10.1016/j.humpath.2011.07.027. Epub 2011 Dec 26. Hum Pathol. 2012. PMID: 22204712
-
Clinical significance of HuR expression in human malignancy.Med Oncol. 2014 Sep;31(9):161. doi: 10.1007/s12032-014-0161-y. Epub 2014 Aug 13. Med Oncol. 2014. PMID: 25112469 Review.
-
HuR function in disease.Front Biosci (Landmark Ed). 2012 Jan 1;17(1):189-205. doi: 10.2741/3921. Front Biosci (Landmark Ed). 2012. PMID: 22201738 Free PMC article. Review.
Cited by
-
BAG3 regulates stability of IL-8 mRNA via interplay between HuR and miR-4312 in PDACs.Cell Death Dis. 2018 Aug 28;9(9):863. doi: 10.1038/s41419-018-0874-5. Cell Death Dis. 2018. PMID: 30154469 Free PMC article.
-
Network based analyses of gene expression profile of LCN2 overexpression in esophageal squamous cell carcinoma.Sci Rep. 2014 Jun 23;4:5403. doi: 10.1038/srep05403. Sci Rep. 2014. PMID: 24954627 Free PMC article.
-
Angustoline Inhibited Esophageal Tumors Through Regulating LKB1/AMPK/ELAVL1/LPACT2 Pathway and Phospholipid Remodeling.Front Oncol. 2020 Jul 7;10:1094. doi: 10.3389/fonc.2020.01094. eCollection 2020. Front Oncol. 2020. PMID: 32733803 Free PMC article.
-
Dysregulation of TTP and HuR plays an important role in cancers.Tumour Biol. 2016 Nov;37(11):14451-14461. doi: 10.1007/s13277-016-5397-z. Epub 2016 Sep 19. Tumour Biol. 2016. PMID: 27644249 Review.
-
Clinical Significance of Hu-Antigen Receptor (HuR) and Cyclooxygenase-2 (COX-2) Expression in Human Malignant and Benign Thyroid Lesions.Pathol Oncol Res. 2016 Jan;22(1):189-96. doi: 10.1007/s12253-015-9997-5. Pathol Oncol Res. 2016. PMID: 26498465
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous